Cargando…
Drug-sensitive FGFR3 mutations in lung adenocarcinoma
BACKGROUND: Lung cancer is the leading cause of cancer-related deaths across the world. In this study, we present therapeutically relevant genetic alterations in lung adenocarcinoma of Indian origin. MATERIALS AND METHODS: Forty-five primary lung adenocarcinoma tumors were sequenced for 676 amplicon...
Autores principales: | Chandrani, P., Prabhash, K., Prasad, R., Sethunath, V., Ranjan, M., Iyer, P., Aich, J., Dhamne, H., Iyer, D. N., Upadhyay, P., Mohanty, B., Chandna, P., Kumar, R., Joshi, A., Noronha, V., Patil, V., Ramaswamy, A., Karpe, A., Thorat, R., Chaudhari, P., Ingle, A., Choughule, A., Dutt, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391708/ https://www.ncbi.nlm.nih.gov/pubmed/27998968 http://dx.doi.org/10.1093/annonc/mdw636 |
Ejemplares similares
-
Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014) -
ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer
por: Iyer, Prajish, et al.
Publicado: (2018) -
NGS-based approach to determine the presence of HPV and their sites of integration in human cancer genome
por: Chandrani, P, et al.
Publicado: (2015) -
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations
por: Joshi, Asim, et al.
Publicado: (2021) -
Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)